Abstract
Prostate biopsies are frequently performed to screen for prostate cancer (PCa) with complications such as infections and bleeding. To reduce unnecessary biopsies, here we designed an improved predictive model of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen (PSA) concentrations for diagnosing PCa and risk stratification. Multiparametric MRI administered to 422 consecutive patients before initial transrectal ultrasonography-guided 13-core prostate biopsies from January 2012 to March 2018 at Fujian Medical University Union Hospital. Univariate and multivariate logistic regression analyses and determination of the area under the curve (AUC) of the receiver operating characteristic (ROC) curve was performed to evaluate and integrate the predictors of PCa and high-risk prostate cancer (HR-PCa). The detection rates of PCa was 43.84% (185/422). And the detection rates of HR-PCa was 71.35% (132/185) in PCa patients. Multivariate analysis revealed that prostate volume(PV), PSA density(PSAD), transitional zone volume(TZV), PSA density of the transitional zone(PSADTZ), and MR were independent predictors of PCa and HR-PCa. PSA, peripheral zone volume(PZV) and PSA density of the peripheral zone(PSADPZ) were independent predictors of PCa but not HR-PCa. The AUC of our best predictive model including PSA + PV + PSAD + MR + TZV or PSA + PV + PSAD + MR + PZV was 0.906 for PCa. The AUC of the best predictive model of PV + PSAD + MR + TZV was 0.893 for HR-PCa. In conclusion, our results will likely improve the detection rate of prostate cancer, avoiding unnecessary prostate biopsies, and for evaluating risk stratification.
Highlights
prostate cancer (PCa) is the most frequent cancer in men[1], with increasing prevalence.[2]
We evaluated the diagnostic accuracy of base model 2 that incorporated the clinical predictors MR, prostate volume (PV) and PSA density (PSAD) as well as the logistic prediction models with transition zone volume (TZV) and with PSADTZ to evaluate biopsy results (HR-PCa or no high-risk prostate cancer (HR-PCa))
Lower PV and TZV values were found in patients with positive biopsies
Summary
PCa is the most frequent cancer in men[1], with increasing prevalence.[2] Screening of PSA can detect PCa at an earlier stage. Elevation of PSA levels in serum requires prostate biopsy to confirm if it is caused by PCa. a biopsy can be painful and may cause complications such as infection and bleeding.[3] Fewer than 50% of patients with elevated PSA levels have positive biopsies (41.49%[4] and 30.7%[5]). The low detection rate is partly explained by the blind approach of transrectal ultrasound scan (TRUS)-prostate biopsy,[6] which leads to a high rate of unnecessary biopsies
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have